Regulation of mRNA translation by signaling pathways

Cold Spring Harbor Perspectives in Biology

Volumn 4, Issue 11, 2012, Pages

  Roux, Philippe P ^a   Topisirovic, Ivan ^b,c  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; TARGET OF RAPAMYCIN KINASE;

ARTICLE; BIOLOGICAL MODEL; GENE EXPRESSION REGULATION; HUMAN; METABOLISM; PHOSPHORYLATION; PHYSIOLOGY; PROTEIN SYNTHESIS; SIGNAL TRANSDUCTION;

GENE EXPRESSION REGULATION; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASES; MODELS, BIOLOGICAL; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROTEIN BIOSYNTHESIS; RNA, MESSENGER; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84868600748     PISSN: None     EISSN: 19430264     Source Type: Journal    
DOI: 10.1101/cshperspect.a012252     Document Type: Article

References (232)

1. Acosta-Jaquez HA, Keller JA, Foster KG, Ekim B, Soliman GA, Feener EP, Ballif BA, Fingar DC. 2009. Site-specific mTOR phosphorylation promotes mTORC1-mediated signaling and cell growth. Mol Cell Biol 29: 4308-4324.
2. Angenstein F, Greenough WT, Weiler IJ. 1998. Metabotropic glutamate receptor-initiated translocation of protein kinase p90rsk to polyribosomes: A possible factor regulating synaptic protein synthesis. Proc Natl Acad Sci 95: 15078-15083.
3. Avruch J, Hara K, Lin Y, Liu M, Long X, Ortiz-Vega S, Yonezaw K. 2006. Insulin and amino-acid regulation of mTOR signaling and kinase activity through the Rhe GTPase. Oncogene 25: 6361-6372.
4. Ballif BA, Roux PP, Gerber SA, MacKeigan JP, Blenis J, Gyg SP. 2005. Quantitative phosphorylation profiling of the ERK/p90 ribosomal S6 kinase-signaling cassette and its targets, the tuberous sclerosis tumor suppressors. Proc Natl Acad Sci 102: 667-672.
5. Bandi HR, Ferrari S, Krieg J, Meyer HE, Thomas G. 1993. Identification of 40 S ribosomal protein S6 phosphorylation sites in Swiss mouse 3T3 fibroblasts stimulated with serum. J Biol Chem 268: 4530-4533.
6. Banerjee P, Ahmad MF, Grove JR, Kozlosky C, Price DJ, Avruch J. 1990. Molecular structure of a major insulin/ mitogen-activated 70-kDa S6 protein kinase. Proc Nat Acad Sci 87: 8550-8554.
7. Beausoleil SA, Jedrychowski M, Schwartz D, Elias JE, Ville J, Li J, Cohn MA, Cantley LC, Gygi SP. 2004. Large-scale characterization of HeLa cell nuclear phosphoproteins. Proc Natl Acad Sci 101: 12130-12135.
8. Benham AM. 2012. Protein secretion and the endoplasmic reticulum. Cold Spring Harb Perspect Biol doi: 10.1101/ cshperspect.a012872.
9. Bermek E, Matthaei H. 1971. Interactions between human translocation factor, guanosine triphosphate, and ribosomes. Biochemistry 10: 4906-4912.
10. Binda M, Peli-Gulli MP, Bonfils G, Panchaud N, Urban J, Sturgill TW, Loewith R, De Virgilio C. 2009. The Vam6 GEF controls TORC1 by activating the EGO complex. Mol Cell 35: 563-573.
11. Braun JE, Huntzinger E, Izaurralde E. 2012. A molecular link between miRISCs and deadenylases provides new insight into the mechanism of gene silencing by micro-RNAs. Cold Spring Harb Perspect Biol doi: 10.1101/ cshperspect.a012328.
12. Brooks RF. 1977. Continuous protein synthesis is required to maintain the probability of entry into S phase. Cell 12: 311-317.
13. Browne GJ, Proud CG. 2004. A novel mTOR-regulated phosphorylation site in elongation factor 2 kinase modulates the activity of the kinase and its binding to calmodulin. Mol Cell Biol 24: 2986-2997.
14. Brugarolas J, Lei K, Hurley RL, Manning BD, Reiling JH, Hafen E, Witters LA, Ellisen LW, Kaelin WG Jr. 2004. Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex. Genes Dev 18: 2893-2904.
15. Brunn GJ, Hudson CC, Sekulic A, Williams JM, Hosoi H, Houghton PJ, Lawrence JC Jr, Abraham RT. 1997. Phosphorylation of the translational repressor PHAS-I by the mammalian target of rapamycin. Science 277: 99-101.
16. Buttgereit F, Brand MD. 1995. A hierarchy of ATP-consuming processes in mammalian cells. Biochem J 312 (Pt 1): 163-167.
17. Buxade M, Parra-Palau JL, Proud CG. 2008. The Mnks: MAP kinase-interacting kinases (MAP kinase signal-integrating kinases). Front Biosci 13: 5359-5373.
18. Cantley LC. 2002. The phosphoinositide 3-kinase pathway. Science 296: 1655-1657.
19. Cargnello M, Roux PP. 2011. Activation and Function of the MAPKs and Their Substrates, the MAPK-Activated Protein Kinases. Microbiol Mol Biol Rev 75: 50-83.
20. Caron E, Ghosh S, Matsuoka Y, Ashton-Beaucage D, Therrie M, Lemieux S, Perreault C, Roux PP, Kitano H. 2010. A comprehensive map of the mTOR signaling network. Mol Syst Biol 6: 453.
21. Carriere A, Cargnello M, Julien LA, Gao H, Bonneil E, Thibaul P, Roux PP. 2008a. Oncogenic MAPK signaling stimulates mTORC1 activity by promoting RSK-mediated raptor phosphorylation. Curr Biol 18: 1269-1277.
22. Carriere A, Ray H, Blenis J, Roux PP. 2008b. The RSK factors of activating the Ras/MAPK signaling cascade. Front Biosci 13: 4258-4275.
23. Carriere A, Romeo Y, Acosta-Jaquez HA, Moreau J, Bonnei E, Thibault P, Fingar DC, Roux PP. 2011. ERK1/2 phosphorylate Raptor to promote Ras-dependent activation of mTOR complex 1 (mTORC1). J Biol Chem 286: 567-577.
24. Ceci M, Gaviraghi C, Gorrini C, Sala LA, Offenhauser N, Marchisio PC, Biffo S. 2003. Release of eIF6 (p27BBP) from the 60S subunit allows 80S ribosome assembly. Nature 426: 579-584.
25. Chen J, Zheng XF, Brown EJ, Schreiber SL. 1995. Identification of an 11-kDa FKBP12-rapamycin-binding domain within the 289-kDa FKBP12-rapamycin-associated protein and characterization of a critical serine residue. Pro Natl Acad Sci 92: 4947-4951.
26. Chen Z, Gibson TB, Robinson F, Silvestro L, Pearson G, X B, Wright A, Vanderbilt C, Cobb MH. 2001. MAP kinases. Chem Rev 101: 2449-2476.
27. Choo AY, Yoon SO, Kim SG, Roux PP, Blenis J. 2008. Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation. Pro Natl Acad Sci 105: 17414-17419.
28. Chung J, Kuo CJ, Crabtree GR, Blenis J. 1992. Rapamycin-FKBP specifically blocks growth-dependent activation of and signaling by the 70 kd S6 protein kinases. Cell 69: 1227-1236.
29. Cohen P, Frame S. 2001. The renaissance of GSK3. Nat Rev Mol Cell Biol 2: 769-776.
30. Colina R, Costa-Mattioli M, Dowling RJ, Jaramillo M, Tai LH, Breitbach CJ, Martineau Y, Larsson O, Rong L, Svitki YV, et al. 2008. Translational control of the innate immune response through IRF-7. Nature 452: 323-328.
31. Corradetti MN, Inoki K, Bardeesy N, DePinho RA, Gua KL. 2004. Regulation of the TSC pathway by LKB1: Evidence of a molecular link between tuberous sclerosis complex and Peutz-Jeghers syndrome. Genes Dev 18: 1533-1538.
32. De Benedetti A, Graff JR. 2004. eIF-4E expression and its role in malignancies and metastases. Oncogene 23: 3189-3199.
33. DeYoung MP, Horak P, Sofer A, Sgroi D, Ellisen LW. 2008. Hypoxia regulates TSC1/2-mTOR signaling and tumor suppression through REDD1-mediated 14-3-3 shuttling. Genes Dev 22: 239-251.
34. Diggle TA, Redpath NT, Heesom KJ, Denton RM. 1998. Regulation of protein-synthesis elongation-factor-2 kinase by cAMP in adipocytes. Biochem J 336: 525-529.
35. Dobrikov M, Dobrikova E, Shveygert M, Gromeier M. 2011. Phosphorylation of eukaryotic translation initiation factor 4G1 (eIF4G1) by protein kinase Ca regulates eIF4G1 binding to Mnk1. Mol Cell Biol 31: 2947-2959.
36. Dorrello NV, Peschiaroli A, Guardavaccaro D, Colburn NH, Sherman NE, Pagano M. 2006. S6K1-and bTRCP-mediated degradation of PDCD4 promotes protein translation and cell growth. Science 314: 467-471.
37. Dowling RJ, Zakikhani M, Fantus IG, Pollak M, Sonenber N. 2007. Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res 67: 10804-10812.
38. Dowling RJ, Topisirovic I, Alain T, Bidinosti M, Fonseca BD, Petroulakis E, Wang X, Larsson O, Selvaraj A, Liu Y, et al. 2010a. mTORC1-mediated cell proliferation, but not cell growth, controlled by the 4E-BPs. Science 328: 1172-1176.
39. Dowling RJ, Topisirovic I, Fonseca BD, Sonenberg N. 2010b. Dissecting the role of mTOR: Lessons from mTOR inhibitors. Biochim Biophys Acta 1804: 433-439.
40. Duran A, Amanchy R, Linares JF, Joshi J, Abu-Baker S, Poroll A, Hansen M, Moscat J, Diaz-MecoMT. 2011. p62 is a key regulator of nutrient sensing in the mTORC1 pathway. Mol Cell 44: 134-146.
41. Ekim B, Magnuson B, Acosta-Jaquez HA, Keller JA, Feener EP, Fingar DC. 2011. mTOR kinase domain phosphorylation promotes mTORC1 signaling, cell growth, and cell cycle progression. Mol Cell Biol 31: 2787-2801.
42. Ellisen LW, Ramsayer KD, Johannessen CM, Yang A, Bepp H, Minda K, Oliner JD, McKeon F, Haber DA. 2002. REDD1, a developmentally regulated transcriptional target of p63 and p53, links p63 to regulation of reactive oxygen species. Mol Cell 10: 995-1005.
43. Engelman JA, Luo J, Cantley LC. 2006. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 7: 606-619.
44. Erikson E, Maller JL. 1985. A protein kinase from Xenopus eggs specific for ribosomal protein S6. Proc Natl Acad Sci 82: 742-746.
45. Erikson E, Maller JL. 1986. Purification and characterization of a protein kinase from Xenopus eggs highly specific for ribosomal protein S6. J Biol Chem 261: 350-355.
46. Fadden P, Haystead TA, Lawrence JC Jr. 1997. Identification of phosphorylation sites in the translational regulator PHAS-I that are controlled by insulin and rapamycin in rat adipocytes. J Biol Chem 272: 10240-10247.
47. Fenton TR, Gout IT. 2011. Functions and regulation of the 70kDa ribosomal S6 kinases. Int J Biochem Cell Biol 43: 47-59.
48. Ferrari S, Bandi HR, Hofsteenge J, Bussian BM, Thomas G. 1991. Mitogen-activated 70K S6 kinase. Identification of in vitro 40 S ribosomal S6 phosphorylation sites. J Bio Chem 266: 22770-22775.
49. Fingar DC, Blenis J. 2004. Target of rapamycin (TOR): An integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene 23: 3151-3171.
50. Fisher TL, Blenis J. 1996. Evidence for two catalytically active kinase domains in pp90rsk. Mol Cell Biol 16: 1212-1219.
51. Fonseca BD, Smith EM, Lee VH, MacKintosh C, Proud CG. 2007. PRAS40 is a target for mammalian target of rapamycin complex 1 and is required for signaling downstream of this complex. J Biol Chem 282: 24514-24524.
52. Foster KG, Acosta-Jaquez HA, Romeo Y, Ekim B, Solima GA, Carriere A, Roux PP, Ballif BA, Fingar DC. 2010. Regulation of mTOR complex 1 (mTORC1) by raptor Ser863 and multisite phosphorylation. J Biol Chem 285: 80-94.
53. Frias MA, Thoreen CC, Jaffe JD, SchroderW, Sculley T, Car SA, Sabatini DM. 2006. mSin1 is necessary for Akt/PKB phosphorylation, and its isoforms define three distinct mTORC2s. Curr Biol 16: 1865-1870.
54. Fukunaga R, Hunter T. 1997. MNK1, a new MAP kinaseactivate protein kinase, isolated by a novel expression screening method for identifying protein kinase substrates. EMBO J 16: 1921-1997.
55. Furic L, Rong L, Larsson O, Koumakpayi IH, Yoshida K, Brueschke A, Petroulakis E, Robichaud N, Pollak M, Gabour LA, et al. 2010. eIF4E phosphorylation promotes tumorigenesis and is associated with prostate cancer progression. Proc Natl Acad Sci 107: 14134-14139.
56. Gaestel M. 2006. MAPKAP kinases-MKs-two's company, three's a crowd. Nat Rev Mol Cell Biol 7: 120-130.
57. Gaestel M. 2008. Specificity of signaling from MAPKs to MAPKAPKs: Kinases' tango nuevo. Front Biosci 13: 6050-6059.
58. Garami A, Zwartkruis FJ, Nobukuni T, Joaquin M, Roccio M, Stocker H, Kozma SC, Hafen E, Bos JL, Thomas G. 2003. Insulin activation of Rheb, a mediator of mTOR/ S6K/4E-BP signaling, is inhibited by TSC1 and 2. Mo Cell 11: 1457-1466.
59. Garcia-Martinez JM, Alessi DR. 2008. mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum-and glucocorticoid-induced protein kinase 1 (SGK1). Biochem J 416: 375-385.
60. Gevaert K, Staes A, Van Damme J, De Groot S, Hugelier K, Demol H, Martens L, Goethals M, Vandekerckhove J. 2005. Global phosphoproteome analysis on human HepG2 hepatocytes using reversed-phase diagonal LC. Proteomics 5: 3589-3599.
61. Gingras AC, Gygi SP, Raught B, Polakiewicz RD, Abraha RT, Hoekstra MF, Aebersold R, Sonenberg N. 1999a. Regulation of 4E-BP1 phosphorylation: A novel two-step mechanism. Genes Dev 13: 1422-1437.
62. Gingras AC, Raught B, Sonenberg N. 1999b. eIF4 initiation factors: Effectors of mRNA recruitment to ribosomes and regulators of translation. Annu Rev Biochem 68: 913-963.
63. Gingras AC, Raught B, Gygi SP, Niedzwiecka A, Miron M, Burley SK, Polakiewicz RD, Wyslouch-Cieszynska A, Aebersold R, Sonenberg N. 2001. Hierarchical phosphorylation of the translation inhibitor 4E-BP1. Genes Dev 15: 2852-2864.
64. Goke A, Goke R, Knolle A, Trusheim H, Schmidt H, Wilmen A, Carmody R, Goke B, Chen YH. 2002. DUG is a novel homologue of translation initiation factor 4G that binds eIF4A. Biochem Biophys Res Commun 297: 78-82.
65. Gout I, Minami T, Hara K, Tsujishita Y, Filonenko V, Waterfield MD, Yonezawa K. 1998. Molecular cloning and characterization of a novel p70 S6 kinase, p70 S6 kinase beta containing a proline-rich region. J Biol Chem 273: 30061-30064.
66. Graff JR, Zimmer SG. 2003. Translational control and metastatic progression: Enhanced activity of the mRNA capbinding protein eIF-4E selectively enhances translation of metastasis-related mRNAs. Clin Exp Metastasis 20: 265-273.
67. Graff JR, Konicek BW, Carter JH, Marcusson EG. 2008. Targeting the eukaryotic translation initiation factor 4E for cancer therapy. Cancer Res 68: 631-634.
68. GreenbaumD, Luscombe NM, Jansen R, Qian J, Gerstein M. 2001. Interrelating different types of genomic data, from proteome to secretome: 'oming in on function. Genom Res 11: 1463-1468.
69. Grifo JA, Abramson RD, Satler CA, Merrick WC. 1984. RNA-stimulated ATPase activity of eukaryotic initiation factors. J Biol Chem 259: 8648-8654.
70. Grove JR, Banerjee P, Balasubramanyam A, Coffer PJ, Price DJ, Avruch J, Woodgett JR. 1991. Cloning and expression of two human p70 S6 kinase polypeptides differing only at their amino termini. Mol Cell Biol 11: 5541-5550.
71. Guertin DA, Sabatini DM. 2007. Defining the role of mTOR in cancer. Cancer Cell 12: 9-22.
72. Guertin DA, Sabatini DM. 2009. The pharmacology of mTOR inhibition. Sci Signal 2: e24.
73. Gwinn DM, Shackelford DB, Egan DF, Mihaylova MM, Mery A, Vasquez DS, Turk BE, Shaw RJ. 2008. AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol Cell 30: 214-226.
74. Hara K, Yonezawa K, Weng QP, Kozlowski MT, Belham C, Avruch J. 1998. Amino acid sufficiency and mTOR regulate p70 S6 kinase and eIF-4E BP1 through a common effector mechanism. J Biol Chem 273: 14484-14494.
75. Hay N, Sonenberg N. 2004. Upstream and downstream of mTOR. Genes Dev 18: 1926-1945.
76. Heesom KJ, Avison MB, Diggle TA, Denton RM. 1998. Insulin-stimulated kinase from rat fat cells that phosphorylates initiation factor 4E-binding protein 1 on the rapamycin-insensitive site (serine-111). Biochem J 336 (Pt 1): 39-48.
77. Holz MK, Ballif BA, Gygi SP, Blenis J. 2005. mTOR and S6K1 mediate assembly of the translation preinitiation complex through dynamic protein interchange and ordered phosphorylation events. Cell 123: 569-580.
78. Homma MK, Wada I, Suzuki T, Yamaki J, Krebs EG, Homm Y. 2005. CK2 phosphorylation of eukaryotic translation initiation factor 5 potentiates cell cycle progression. Pro Natl Acad Sci 102: 15688-15693.
79. Horman S, Browne G, Krause U, Patel J, Vertommen D, Bertrand L, Lavoinne A, Hue L, Proud C, Rider M. 2002. Activation of AMP-activated protein kinase leads to the phosphorylation of elongation factor 2 and an inhibition of protein synthesis. Curr Biol 12: 1419-1423.
80. Howell JJ, Manning BD. 2011. mTOR couples cellular nutrient sensing to organismal metabolic homeostasis. Trends Endocrinol Metab 22: 94-102.
81. Inoki K, Li Y, Xu T, Guan KL. 2003. Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. Genes Dev 17: 1829-1834.
82. Jacinto E, Facchinetti V, Liu D, Soto N, Wei S, Jung SY, Huang Q, Qin J, Su B. 2006. SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity. Cell 127: 125-137.
83. Jackson RJ, Hellen CU, Pestova TV. 2010. The mechanism of eukaryotic translation initiation and principles of its regulation. Nat Rev Mol Cell Biol 11: 113-127.
84. Jefferies HB, Reinhard C, Kozma SC, Thomas G. 1994. Rapamycin selectively represses translation of the "polypyrimidine tract" mRNA family. Proc Natl Acad Sci 91: 4441-4445.
85. Johannessen CM, Reczek EE, James MF, Brems H, Legius E, Cichowski K. 2005. The NF1 tumor suppressor critically regulates TSC2 and mTOR. Proc Natl Acad Sci 102: 8573-8578.
86. Johannessen CM, Johnson BW, Williams SM, Chan AW, Reczek EE, Lynch RC, Rioth MJ, McClatchey A, Ryeo S, Cichowski K. 2008. TORC1 is essential for NF1-associated malignancies. Curr Biol 18: 56-62.
87. JonesSW, Erikson E, Blenis J, Maller JL, Erikson RL. 1988. A Xenopus ribosomal protein S6 kinase has two apparent kinase domains that are each similar to distinct protein kinases. Proc Natl Acad Sci 85: 3377-3381.
88. Joshi B, Cai AL, Keiper BD, Minich WB, Mendez R, Beach CM, Stepinski J, Stolarski R, Darzynkiewicz E, Rhoad RE. 1995. Phosphorylation of eukaryotic protein synthesis initiation factor 4E at Ser-209. J Biol Chem 270: 14597-14603.
89. Kahn BB, Alquier T, Carling D, Hardie DG. 2005. AMPactivated protein kinase: Ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab 1: 15-25.
90. Kantidakis T, Ramsbottom BA, Birch JL, Dowding SN, White RJ. 2010. mTOR associates with TFIIIC, is found at tRNA and 5S rRNA genes, and targets their represso Maf1. Proc Natl Acad Sci 107: 11823-11828.
91. Kaspar RL, Rychlik W, White MW, Rhoads RE, Morris DR. 1990. Simultaneous cytoplasmic redistribution of ribosomal protein L32 mRNA and phosphorylation of eukaryotic initiation factor 4E after mitogenic stimulation of Swiss 3T3 cells. J Biol Chem 265: 3619-3622.
92. Kawasome H, Papst P, Webb S, Keller GM, Johnson GL, Gelfand EW, Terada N. 1998. Targeted disruption of p70(s6k) defines its role in protein synthesis and rapamycin sensitivity. Proc Natl Acad Sci 95: 5033-5038.
93. Kielbassa K, Muller HJ, Meyer HE, Marks F, Gschwendt M. 1995. Protein kinase C delta-specific phosphorylation of the elongation factor eEF-alpha and an eEF-1 alpha peptide at threonine 431. J Biol Chem 270: 6156-6162.
94. Kim J, Guan KL. 2011. Amino acid signaling in TOR activation. Annu Rev Biochem 80: 1001-1032.
95. Kim JE, Tannenbaum SR, White FM. 2005. Global phosphoproteome of HT-29 human colon adenocarcinoma cells. J Proteome Res 4: 1339-1346.
96. Kim E, Goraksha-Hicks P, Li L, Neufeld TP, Guan KL. 2008. Regulation of TORC1 by Rag GTPases in nutrient response. Nat Cell Biol 10: 935-945.
97. Knauf U, Tschopp C, Gram H. 2001. Negative regulation of protein translation by mitogen-activated protein kinaseinteracting kinases 1 and 2. Mol Cell Biol 21: 5500-5511.
98. Knebel A, Morrice N, Cohen P. 2001. A novel method to identify protein kinase substrates: eEF2 kinase is phosphorylated and inhibited by SAPK4/p38delta. EMBO J 20: 4360-4369.
99. Koromilas AE, Lazaris-Karatzas A, Sonenberg N. 1992. mRNAs containing extensive secondary structure in their 5′noncoding region translate efficiently in cells overexpressing initiation factor eIF-4E. EMBO J 11: 4153-4158.
100. Kozma SC, Ferrari S, Bassand P, Siegmann M, Totty N, Thoma G. 1990. Cloning of the mitogen-activated S6 kinase from rat liver reveals an enzyme of the second messenger subfamily. Proc Natl Acad Sci 87: 7365-7369.
101. Krieg J, Hofsteenge J, Thomas G. 1988. Identification of the 40 S ribosomal protein S6 phosphorylation sites induced by cycloheximide. J Biol Chem 263: 11473-11477.
102. KudlickiW, Wettenhall RE, Kemp BE, Szyszka R, Kramer G, Hardesty B. 1987. Evidence for a second phosphorylation site on eIF-2 alpha from rabbit reticulocytes. FEBS Lett 215: 16-20.
103. Kwiatkowski DJ, Manning BD. 2005. Tuberous sclerosis: a GAP at the crossroads of multiple signaling pathways. Hum Mol Genet 14 (Spec No 2): R251-R258.
104. Kyriakis JM, Avruch J. 2001. Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol Rev 81: 807-869.
105. Lachance PE, Miron M, Raught B, Sonenberg N, Lasko P. 2002. Phosphorylation of eukaryotic translation initiation factor 4E is critical for growth. Mol Cell Biol 22: 1656-1663.
106. Lankat-Buttgereit B, Goke R. 2009. The tumour suppressor Pdcd4: Recent advances in the elucidation of function and regulation. Biol Cell 101: 309-317.
107. Laplante M, Sabatini DM. 2009. mTORsignaling at a glance. J Cell Sci 122 (Pt 20): 3589-3594.
108. Lasko P. 2012. mRNA localization and translational control in Drosophila oogenesis. Cold Spring Harb Perspect Biol doi: 10.1101/cshperspect.a012294.
109. Levy S, Avni D, Hariharan N, Perry RP, Meyuhas O. 1991. Oligopyrimidine tract at the 5′end of mammalian ribosomal protein mRNAs is required for their translational control. Proc Natl Acad Sci 88: 3319-3323.
110. Li Y, Wang Y, Kim E, Beemiller P, Wang CY, Swanson J, Yo M, Guan KL. 2007. Bnip3 mediates the hypoxia-induced inhibition on mammalian target of rapamycin by interacting with Rheb. J Biol Chem 282: 35803-35813.
111. Lin KW, Yakymovych I, Jia M, Yakymovych M, Souchelnytsky S. 2010. Phosphorylation of eEF1A1 at Ser300 by TbetaR-I results in inhibition of mRNA translation. Curr Biol 20: 1615-1625.
112. Ling J, Morley SJ, Traugh JA. 2005. Inhibition of cap-dependent translation via phosphorylation of eIF4G by protein kinase Pak2. EMBO J 24: 4094-4105.
113. Loreni F, Thomas G, Amaldi F. 2000. Transcription inhibitors stimulate translation of 5′TOP mRNAs through activation of S6 kinase and the mTOR/FRAP signalling pathway. Eur J Biochem 267: 6594-6601.
114. Lynch M, Fitzgerald C, Johnston KA, Wang S, Schmidt EV. 2004. Activated eIF4E-binding protein slows G1 progression and blocks transformation by c-myc without inhibiting cell growth. J Biol Chem 279: 3327-3339.
115. Ma L, Chen Z, Erdjument-Bromage H, Tempst P, Pandolf PP. 2005. Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis. Cell 121: 179-193.
116. Ma XM, Blenis J. 2009. Molecular mechanisms of mTORmediated translational control. Nat Rev Mol Cell Biol 10: 307-318.
117. Ma XM, Yoon SO, Richardson CJ, Julich K, Blenis J. 2008. SKAR links pre-mRNA splicing to mTOR/S6K1-mediated enhanced translation efficiency of spliced mRNAs. Cell 133: 303-313.
118. Maehama T, Dixon JE. 1998. The tumor suppressor, PTEN/ MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem 273: 13375-13378.
119. Malina A, Mills JR, Pelletier J. 2012. Emerging therapeutics targeting mRNA translation. Cold Spring Harb Perspect Biol doi: 10.1101/cshperspect.a012377.
120. Manning BD, Tee AR, Logsdon MN, Blenis J, Cantley LC. 2002. Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway. Mol Cell 10: 151-162.
121. Manzella JM, Rychlik W, Rhoads RE, Hershey JW, Blackshea PJ. 1991. Insulin induction of ornithine decarboxylase. Importance of mRNA secondary structure and phosphorylation of eucaryotic initiation factors eIF-4B and eIF-4E. J Biol Chem 266: 2383-2389.
122. Marcotrigiano J, Gingras AC, Sonenberg N, Burley SK. 1997. Cocrystal structure of the messenger RNA 5′cap-binding protein (eIF4E) bound to 7-methyl-GDP. Cell 89: 951-961.
123. Mathews MB, Sonenberg N, Hershey JWB. 2007. Translational control in biology and medicine. In Translational control in biology and medicine (ed. NS Michael, B Mathews, W John, B Hershey). Cold Spring Harbor Laboratory Press, Cold Spring, NY.
124. Matsuo H, Li H, McGuire AM, Fletcher CM, Gingras AC, Sonenberg N, Wagner G. 1997. Structure of translation factor eIF4E bound to m7GDP and interaction with 4Ebinding protein. Nat Struct Biol 4: 717-724.
125. Mayer C, Zhao J, Yuan X, Grummt I. 2004. mTOR-dependent activation of the transcription factor TIF-IA links rRNA synthesis to nutrient availability. Genes Dev 18: 423-434.
126. Meyuhas O. 2008. Physiological roles of ribosomal protein S6: One of its kind. Int Rev Cell Mol Biol 268: 1-37.
127. Michels AA, Robitaille AM, Buczynski-Ruchonnet D, Hodro W, Reina JH, Hall MN, Hernandez N. 2010. mTORC1 directly phosphorylates and regulates huma MAF1. Mol Cell Biol 30: 3749-3757.
128. Miron M, Verdu J, Lachance PE, Birnbaum MJ, Lasko PF, Sonenberg N. 2001. The translational inhibitor 4E-BP is an effector of PI(3)K/Akt signalling and cell growth in Drosophila. Nat Cell Biol 3: 596-601.
129. Montagne J, Stewart MJ, Stocker H, Hafen E, Kozma SC, Thomas G. 1999. Drosophila S6 kinase: A regulator of cell size. Science 285: 2126-2129.
130. Morley SJ, Naegele S. 2002. Phosphorylation of eukaryotic initiation factor (eIF) 4E is not required for de novo protein synthesis following recovery from hypertonic stress in human kidney cells. J Biol Chem 277: 32855-32859.
131. Naegele S, Morley SJ. 2004. Molecular cross-talk between MEK1/2 and mTOR signaling during recovery of 293 cells from hypertonic stress. J Biol Chem 279: 46023-46034.
132. Nairn AC, Palfrey HC. 1987. Identification of the major Mr 100000 substrate for calmodulin-dependent protein kinase III in mammalian cells as elongation factor-2. J Bio Chem 262: 17299-17303.
133. Oh WJ, Jacinto E. 2011. mTOR complex 2 signaling and functions. Cell Cycle 10: 2305-2316.
134. Oh WJ, Wu CC, Kim SJ, Facchinetti V, Julien LA, Finlan M, Roux PP, Su B, Jacinto E. 2010. mTORC2 can associate with ribosomes to promote cotranslational phosphorylation and stability of nascent Akt polypeptide. EMBO J 29: 3939-3951.
135. Ohanna M, Sobering AK, Lapointe T, Lorenzo L, Praud C, Petroulakis E, Sonenberg N, Kelly PA, Sotiropoulos A, Pende M. 2005. Atrophy of S6K1(-/-) skeletal muscle cells reveals distinct mTOR effectors for cell cycle and size control. Nat Cell Biol 7: 286-294.
136. Oshiro N, Takahashi R, Yoshino K, Tanimura K, Nakashima A, Eguchi S, Miyamoto T, Hara K, Takehana K, Avruch J, et al. 2007. The proline-rich Akt substrate of 40 kDa (PRAS40) is a physiological substrate of mammalian target of rapamycin complex 1. J Biol Chem 282: 20329-20339.
137. Palamarchuk A, Efanov A, Maximov V, Aqeilan RI, Croc CM, Pekarsky Y. 2005. Akt phosphorylates and regulate Pdcd4 tumor suppressor protein. Cancer Res 65: 11282-11286.
138. Pause A, Belsham GJ, Gingras AC, Donze O, Lin TA, Lawrenc JC Jr, Sonenberg N. 1994. Insulin-dependent stimulation of protein synthesis by phosphorylation of a regulator of 5′-cap function. Nature 371: 762-767.
139. Pavitt GD, Ron D. 2012. New insights into translational regulation in the endoplasmic reticulum unfolded protein response. Cold Spring Harb Perspect Biol doi: 10.1101/cshperspect.a012278.
140. Pearce LR, Huang X, Boudeau J, Pawlowski R, Wullschleger S, Deak M, Ibrahim AF, Gourlay R, Magnuson MA, Alessi DR. 2007. Identification of Protor as a novel Rictor-binding component of mTOR complex-2. Biochem J 405: 513-522.
141. Pearce LR, KomanderD, Alessi DR. 2010. The nuts and bolts of AGC protein kinases. Nat Rev Mol Cell Biol 11: 9-22.
142. Pearson G, Robinson F, Beers Gibson T, Xu BE, Karandikar M, Berman K, Cobb MH. 2001. Mitogen-activated protein (MAP) kinase pathways: Regulation and physiological functions. Endocr Rev 22: 153-183.
143. Pende M, Um SH, Mieulet V, Sticker M, Goss VL, Mestan J, Mueller M, Fumagalli S, Kozma SC, Thomas G. 2004. S6K1(-/-)/S6K2(-/-) mice exhibit perinatal lethality and rapamycin-sensitive 5′-terminal oligopyrimidine mRNA translation and reveal a mitogen-activated protein kinase-dependent S6 kinase pathway. Mol Cell Biol 24: 3112-3124.
144. Peterson TR, Laplante M, Thoreen CC, Sancak Y, Kang SA, Kuehl WM, Gray NS, Sabatini DM. 2009. DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival. Cell 137: 873-886.
145. Petroulakis E, Mamane Y, Le Bacquer O, Shahbazian D, Sonenberg N. 2006. mTOR signaling: Implications for cancer and anticancer therapy. Br J Cancer 94: 195-199.
146. Petroulakis E, Parsyan A, Dowling RJ, LeBacquer O, Martineau Y, Bidinosti M, LarssonO, Alain T, Rong L, Maman Y, et al. 2009. p53-dependent translational control of senescence and transformation via 4E-BPs. Cancer Cell 16: 439-446.
147. Piazzi M, Bavelloni A, Faenza I, Blalock W, Urbani A, D'Aguanno S, Fiume R, Ramazzotti G, Maraldi NM, Cocco L. 2010. eEF1A phosphorylation in the nucleus of insulin-stimulated C2C12 myoblasts: Ser(3) is a novel substrate for protein kinase C betaI. Mol Cell Proteomics 9: 2719-2728.
148. Price NT, Redpath NT, Severinov KV, Campbell DG, Russel JM, Proud CG. 1991. Identification of the phosphorylation sites in elongation factor-2 from rabbit reticulocytes. FEBS Lett 282: 253-258.
149. Pyronnet S, Imataka H, Gingras AC, Fukunaga R, Hunte T, Sonenberg N. 1999. Human eukaryotic translation initiation factor 4G (eIF4G) recruits mnk1 to phosphorylate eIF4E. EMBO J 18: 270-279.
150. Rajalingam K, Schreck R, Rapp UR, Albert S. 2007. Ras oncogenes and their downstream targets. Biochim Biophy Acta 1773: 1177-1195.
151. Ramirez-Valle F, Braunstein S, Zavadil J, Formenti SC, Schneider RJ. 2008. eIF4GI links nutrient sensing by mTOR to cell proliferation and inhibition of autophagy. J Cell Biol 181: 293-307.
152. Rapley J, Oshiro N, Ortiz-Vega S, Avruch J. 2011. The mechanism of insulin-stimulated 4E-BP protein binding to mammalian target of rapamycin (mTOR) complex 1 and its contribution to mTOR complex 1 signaling. J Biol Chem 286: 38043-38053.
153. Raught B, Gingras AC, Gygi SP, Imataka H, Morino S, Grad A, Aebersold R, Sonenberg N. 2000. Serum-stimulated, rapamycin-sensitive phosphorylation sites in the eukaryotic translation initiation factor 4GI. EMBO J 19: 434-444.
154. Raught B, Peiretti F, Gingras AC, Livingstone M, Shahbazian D, Mayeur GL, Polakiewicz RD, Sonenberg N, Hershe JW. 2004. Phosphorylation of eucaryotic translation initiation factor 4B Ser422 is modulated by S6 kinases. EMBO J 23: 1761-1769.
155. Richardson CJ, Broenstrup M, Fingar DC, Julich K, Balli BA, Gygi S, Blenis J. 2004. SKAR is a specific target of S6 kinase 1 in cell growth control. Curr Biol 14: 1540-1549.
156. Richter-Cook NJ, Dever TE, Hensold JO, MerrickWC. 1998. Purification and characterization of a new eukaryotic protein translation factor. Eukaryotic initiation factor 4H. J Biol Chem 273: 7579-7587.
157. Rogers GW Jr, Richter NJ, Lima WF, Merrick WC. 2001. Modulation of the helicase activity of eIF4A by eIF4B, eIF4H, and eIF4F. J Biol Chem 276: 30914-30922.
158. Roux PP, Blenis J. 2004. ERK and p38 MAPK-activated protein kinases: A family of protein kinases with diverse biological functions. Microbiol Mol Biol Rev 68: 320-344.
159. Roux PP, Ballif BA, Anjum R, Gygi SP, Blenis J. 2004. Tumorpromoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase. Proc Natl Acad Sci 101: 13489-13494.
160. Roux PP, Shahbazian D, Vu H, Holz MK, Cohen MS, Taunto J, Sonenberg N, Blenis J. 2007. RAS/ERK signaling promotes site-specific ribosomal protein S6 phosphorylation via RSK and stimulates cap-dependent translation. J Biol Chem 282: 14056-14064.
161. Rozen F, Edery I, Meerovitch K, Dever TE, Merrick WC, Sonenberg N. 1990. Bidirectional RNA helicase activity of eucaryotic translation initiation factors 4A and 4F. Mo Cell Biol 10: 1134-1144.
162. Rush J, Moritz A, Lee KA, Guo A, Goss VL, Spek EJ, Zhan H, Zha XM, Polakiewicz RD, Comb MJ. 2005. Immunoaffinity profiling of tyrosine phosphorylation in cancer cells. Nat Biotechnol 23: 94-101.
163. Ruvinsky I, Sharon N, Lerer T, Cohen H, Stolovich-Rain M, Nir T, Dor Y, Zisman P, Meyuhas O. 2005. Ribosomal protein S6 phosphorylation is a determinant of cell size and glucose homeostasis. Genes Dev 19: 2199-2211.
164. Sancak Y, Thoreen CC, Peterson TR, Lindquist RA, Kang SA, Spooner E, Carr SA, Sabatini DM. 2007. PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase. Mol Cell 25: 903-915.
165. Sancak Y, Peterson TR, Shaul YD, Lindquist RA, Thoree CC, Bar-Peled L, Sabatini DM. 2008. The Rag GTPases bind raptor and mediate amino acid signaling to mTORC1. Science 320: 1496-1501.
166. Sancak Y, Bar-Peled L, Zoncu R, Markhard AL, Nada S, Sabatini DM. 2010. Ragulator-Rag complex targets mTORC1 to the lysosomal surface and is necessary for its activation by amino acids. Cell 141: 290-303.
167. Sarbassov DD, Ali SM, Kim DH, Guertin DA, Latek RR, Erdjument-Bromage H, Tempst P, Sabatini DM. 2004. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol 14: 1296-1302.
168. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. 2005. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307: 1098-1101.
169. SarbassovDD, Ali SM, Sengupta S, Sheen JH, Hsu PP, Bagle AF, Markhard AL, Sabatini DM. 2006. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/ PKB. Mol Cell 22: 159-168.
170. Schalm SS, Blenis J. 2002. Identification of a conserved motif required for mTOR signaling. Curr Biol 12: 632-639.
171. Schalm SS, Fingar DC, Sabatini DM, Blenis J. 2003. TOS motif-mediated raptor binding regulates 4E-BP1 multisite phosphorylation and function. Curr Biol 13: 797-806.
172. Scheper GC, Morrice NA, Kleijn M, Proud CG. 2001. The mitogen-activated protein kinase signal-integrating kinase Mnk2 is a eukaryotic initiation factor 4E kinase with high levels of basal activity in mammalian cells. Mol Cell Biol 21: 743-754.
173. Scheper GC, van Kollenburg B, Hu J, Luo Y, Goss DJ, Prou CG. 2002. Phosphorylation of eukaryotic initiation factor 4E markedly reduces its affinity for capped mRNA. J Biol Chem 277: 3303-3309.
174. Schwanhausser B, Busse D, Li N, Dittmar G, Schuchhardt J, Wolf J, Chen W, Selbach M. 2011. Global quantification of mammalian gene expression control. Nature 473: 337-342.
175. Sengupta S, Peterson TR, Sabatini DM. 2010. Regulation of the mTOR complex 1 pathway by nutrients, growth factors, and stress. Mol Cell 40: 310-322.
176. Shahbazian D, Roux PP, Mieulet V, Cohen MS, Raught B, Taunton J, Hershey JW, Blenis J, Pende M, Sonenberg N. 2006. The mTOR/PI3K and MAPK pathways converge on eIF4B to control its phosphorylation and activity. EMBO J 25: 2781-2791.
177. Shahbazian D, Parsyan A, Petroulakis E, Topisirovic I, Martinea Y, Gibbs BF, Svitkin Y, Sonenberg N. 2010. Control of cell survival and proliferation by mammalian eukaryotic initiation factor 4B. Mol Cell Biol 30: 1478-1485.
178. Shaw RJ. 2009. LKB1 and AMP-activated protein kinase control of mTOR signalling and growth. Acta Physiol (Oxf) 196: 65-80.
179. Shaw RJ, Cantley LC. 2006. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 441: 424-430.
180. Shaw RJ, Bardeesy N, Manning BD, Lopez L, Kosmatka M, DePinho RA, Cantley LC. 2004. The LKB1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell 6: 91-99.
181. Shi J, Feng Y, Goulet AC, Vaillancourt RR, Sachs NA, Hershe JW, Nelson MA. 2003. The p34cdc2-related cyclindependent kinase 11 interacts with the p47 subunit of eukaryotic initiation factor 3 during apoptosis. J Bio Chem 278: 5062-5071.
182. Shi J, Hershey JW, Nelson MA. 2009. Phosphorylation of the eukaryotic initiation factor 3f by cyclin-dependent kinase 11 during apoptosis. FEBS Lett 583: 971-977.
183. Shima H, Pende M, Chen Y, Fumagalli S, Thomas G, Kozm SC. 1998. Disruption of the p70(s6k)/p85(s6k) gene reveals a small mouse phenotype and a new functional S6 kinase. EMBO J 17: 6649-6659.
184. Shin S, Wolgamott L, Yu Y, Blenis J, Yoon SO. 2011. Glycogen synthase kinase (GSK)-3 promotes p70 ribosomal protein S6 kinase (p70S6K) activity and cell proliferation. Proc Natl Acad Sci 108: 1204-1213.
185. Shor B, Wu J, Shakey Q, Toral-Barza L, Shi C, Follettie M, Y K. 2010. Requirement of the mTOR kinase for the regulation of Maf1 phosphorylation and control of RNA polymerase III-dependent transcription in cancer cells. J Biol Chem 285: 15380-15392.
186. Silvera D, Formenti SC, Schneider RJ. 2010. Translational control in cancer. Nat Rev Cancer 10: 254-266.
187. Skogerson L, Moldave K. 1968. Characterization of the interaction of aminoacyltransferase II with ribosomes. Binding of transferase II and translocation of peptidyl transfer ribonucleic acid. J Biol Chem 243: 5354-5360.
188. Slepenkov SV, Darzynkiewicz E, Rhoads RE. 2006. Stoppedflow kinetic analysis of eIF4E and phosphorylated eIF4E binding to cap analogs and capped oligoribonucleotides: Evidence for a one-step binding mechanism. J Biol Chem 281: 14927-14938.
189. Soliman GA, Acosta-Jaquez HA, Dunlop EA, Ekim B, Ma NE, Tee AR, Fingar DC. 2010. mTORSer-2481 autophosphorylation monitors mTORC-specific catalytic activity and clarifies rapamycin mechanism of action. J Biol Chem 285: 7866-7879.
190. Sonenberg N. 2008. eIF4E, the mRNA cap-binding protein: From basic discovery to translational research. Biochem Cell Biol 86: 178-183.
191. Sonenberg N, Hinnebusch AG. 2009. Regulation of translation initiation in eukaryotes:Mechanisms and biological targets. Cell 136: 731-745.
192. Sonenberg N, Mathews MB, Hershey JWB. 2012. Principles of translational control. Cold Spring Harb Perspect Biol doi: 10.1101/cshperspect.a011528.
193. Stipanuk MH. 2009. Macroautophagy and its role in nutrient homeostasis. Nutr Rev 67: 677-689.
194. Sutherland C, Leighton IA, Cohen P. 1993. Inactivation of glycogen synthase kinase-3 beta by phosphorylation: New kinase connections in insulin and growth-factor signalling. Biochem J 296: 15-19.
195. Svitkin YV, Pause A, Haghighat A, Pyronnet S, Witherell G, Belsham GJ, Sonenberg N. 2001. The requirement for eukaryotic initiation factor 4A (elF4A) in translation is in direct proportion to the degree of mRNA 5′secondary structure. RNA 7: 382-394.
196. Tang H, Hornstein E, Stolovich M, Levy G, Livingstone M, Templeton D, Avruch J, Meyuhas O. 2001. Amino acidinduced translation of TOPmRNAs is fully dependent on phosphatidylinositol 3-kinase-mediated signaling, is partially inhibited by rapamycin, and is independent o S6K1 and rpS6 phosphorylation. Mol Cell Biol 21: 8671-8683.
197. Thedieck K, Polak P, Kim ML, Molle KD, Cohen A, Jeno P, Arrieumerlou C, Hall MN. 2007. PRAS40 and PRR5-like protein are new mTOR interactors that regulate apoptosis. PLoS ONE 2: e1217.
198. Topisirovic I, Ruiz-Gutierrez M, Borden KL. 2004. Phosphorylation of the eukaryotic translation initiation factor eIF4E contributes to its transformation andmRNAtransport activities. Cancer Res 64: 8639-8642.
199. Topisirovic I, Svitkin YV, Sonenberg N, Shatkin AJ. 2011. Cap and cap-binding proteins in the control of gene expression. RNA 2: 277-298.
200. Ueda T, Watanabe-Fukunaga R, Fukuyama H, Nagata S, Fukunaga R. 2004. Mnk2 and Mnk1 are essential for constitutive and inducible phosphorylation of eukaryotic initiation factor 4E but not for cell growth or development. Mol Cell Biol 24: 6539-6549.
201. Vander Haar E, Lee SI, Bandhakavi S, Griffin TJ, Kim DH. 2007. Insulin signalling to mTOR mediated by the Akt/ PKB substrate PRAS40. Nat Cell Biol 9: 316-323.
202. van Gorp AG, van der Vos KE, Brenkman AB, Bremer A, van den Broek N, Zwartkruis F, Hershey JW, Burgering BM, Calkhoven CF, Coffer PJ. 2009. AGC kinases regulate phosphorylation and activation of eukaryotic translation initiation factor 4B. Oncogene 28: 95-106.
203. Walsh D, Mohr I. 2004. Phosphorylation of eIF4E by Mnk-1 enhances HSV-1 translation and replication in quiescent cells. Genes Dev 18: 660-672.
204. Wang X, Campbell LE, Miller CM, Proud CG. 1998. Amino acid availability regulates p70 S6 kinase and multiple translation factors. Biochem J 334 (Pt 1): 261-267.
205. Wang X, LiW, Williams M, Terada N, Alessi DR, Proud CG. 2001a. Regulation of elongation factor 2 kinase by p90(RSK1) and p70 S6 kinase. EMBO J 20: 4370-4379.
206. Wang X, Paulin FE, Campbell LE, Gomez E, O'Brien K, Morrice N, Proud CG. 2001b. Eukaryotic initiation factor 2B: Identification of multiple phosphorylation sites in the epsilon-subunit and their functions in vivo. EMBO J 20: 4349-4359.
207. Wang X, LiW, Parra JL, Beugnet A, Proud CG. 2003. The C terminus of initiation factor 4E-binding protein 1 contains multiple regulatory features that influence its function and phosphorylation. Mol Cell Biol 23: 1546-1557.
208. Wang X, Beugnet A, Murakami M, Yamanaka S, Proud CG. 2005. Distinct signaling events downstream of mTOR cooperate to mediate the effects of amino acids and insulin on initiation factor 4E-binding proteins. Mol Cel Biol 25: 2558-2572.
209. Wang L, Harris TE, Roth RA, Lawrence JC Jr. 2007. PRAS40 regulates mTORC1 kinase activity by functioning as a direct inhibitor of substrate binding. J Biol Chem 282: 20036-20044.
210. Waskiewicz AJ, Flynn A, Proud CG, Cooper JA. 1997. Mitogen-activated protein kinases activate the serine/threonine kinases Mnk1 and Mnk2. Embo J 16: 1909-1920.
211. Wei Y, Tsang CK, Zheng XF. 2009. Mechanisms of regulation of RNA polymerase III-dependent transcription b TORC1. EMBO J 28: 2220-2230.
212. Wek RC, Jiang HY, Anthony TG. 2006. Coping with stress: eIF2 kinases and translational control. Biochem Soc Trans 34(Pt 1): 7-11.
213. Welsh GI, Miller CM, Loughlin AJ, Price NT, Proud CG. 1998. Regulation of eukaryotic initiation factor eIF2B: Glycogen synthase kinase-3 phosphorylates a conserved serine which undergoes dephosphorylation in response to insulin. FEBS Lett 421: 125-130.
214. Wendel HG, Silva RL, Malina A, Mills JR, Zhu H, Ueda T, Watanabe-Fukunaga R, Fukunaga R, Teruya-Feldstein J, Pelletier J, et al. 2007. Dissecting eIF4E action in tumorigenesis. Genes Dev 21: 3232-3237.
215. Widmann C, Gibson S, Jarpe MB, Johnson GL. 1999. Mitogen-activated protein kinase: Conservation of a threekinase module from yeast to human. Physiol Rev 79: 143-180.
216. Woo SY, Kim DH, Jun CB, Kim YM, Haar EV, Lee SI, Heg JW, Bandhakavi S, Griffin TJ. 2007. PRR5, a novel component of mTOR complex 2, regulates platelet-derived growth factor receptor beta expression and signaling. J Biol Chem 282: 25604-25612.
217. Woods YL, Cohen P, BeckerW, Jakes R, Goedert M, Wang X, Proud CG. 2001. The kinase DYRK phosphorylates protein-synthesis initiation factor eIF2Bepsilon at Ser539 and the microtubule-associated protein tau at Thr212: Potential role for DYRK as a glycogen synthase kinase 3-priming kinase. Biochem J 355 (Pt 3): 609-615.
218. Worch J, Tickenbrock L, Schwable J, Steffen B, Cauvet T, Mlody B, Buerger H, Koeffler HP, Berdel WE, Serve H, et al. 2004. The serine-threonine kinase MNK1 is post-translationally stabilized by PML-RARalpha and regulates differentiation of hematopoietic cells. Oncogene 23: 9162-9172.
219. Wullschleger S, Loewith R, Hall MN. 2006. TORsignaling in growth and metabolism. Cell 124: 471-484.
220. Yamagata K, Sanders LK, Kaufmann WE, YeeW, Barnes CA, Nathans D, Worley PF. 1994. rheb, a growth factor-and synaptic activity-regulated gene, encodes a novel Ras-related protein. J Biol Chem 269: 16333-16339.
221. Yang HS, Jansen AP, Komar AA, Zheng X, Merrick WC, Costes S, Lockett SJ, Sonenberg N, Colburn NH. 2003. The transformation suppressor Pdcd4 is a novel eukaryotic translation initiation factor 4A binding protein that inhibits translation. Mol Cell Biol 23: 26-37.
222. Yea SS, FrumanDA. 2011. Cell signaling. New mTORtarget Grb attention. Science 332: 1270-1271.
223. Yip CK, Murata K, Walz T, Sabatini DM, Kang SA. 2010. Structure of the human mTOR complex I and its implications for rapamycin inhibition. Mol Cell 38: 768-774.
224. Zeniou M, Ding T, Trivier E, Hanauer A. 2002. Expression analysis of RSK gene family members: The RSK2 gene, mutated in Coffin-Lowry syndrome, is prominently expressed in brain structures essential for cognitive function and learning. Hum Mol Genet 11: 2929-2940.
225. Zetterberg A, Larsson O, Wiman KG. 1995. What is the restriction point? Curr Opin Cell Biol 7: 835-842.
226. Zhang L, Smit-McBride Z, Pan X, Rheinhardt J, Hershey JW. 2008. An oncogenic role for the phosphorylated h-subunit of human translation initiation factor eIF3. J Bio Chem 283: 24047-24060.
227. Zhao J, Yuan X, Frodin M, Grummt I. 2003. ERK-dependent phosphorylation of the transcription initiation factor TIF-IA is required for RNA polymerase I transcription and cell growth. Mol Cell 11: 405-413.
228. Zhao Y, Xiong X, Sun Y. 2011. DEPTOR, an mTOR inhibitor, is a physiological substrate of SCF(betaTrCP) E3 ubiquitin ligase and regulates survival and autophagy. Mol Cell 44: 304-316.
229. Zhou M, Sandercock AM, Fraser CS, Ridlova G, Stephens E, Schenauer MR, Yokoi-Fong T, Barsky D, Leary JA, Hershe JW, et al. 2008. Mass spectrometry reveals modularity and a complete subunit interaction map of the eukaryotic translation factor eIF3. Proc Natl Acad Sci 105: 18139-18144.
230. Zinzalla V, Stracka D, Oppliger W, Hall MN. 2011. Activation of mTORC2 by association with the ribosome. Cell 144: 757-768.
231. Zoncu R, Bar-Peled L, Efeyan A, Wang S, Sancak Y, Sabatin DM. 2011a. mTORC1 senses lysosomal amino acids through an inside-out mechanism that requires the vacuolar H-ATPase. Science 334: 678-683.
232. Zoncu R, Efeyan A, Sabatini DM. 2011b. mTOR: From growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol 12: 21-35.